Radicut Suspension approved in Korea for the treatment of ALS

Japan’s Tanabe Pharma, formerly known as Mitsubishi Tanabe and now owned by Bain Capital, has obtained approval from the Ministry of Food and Drug Safety in South Korea to Radicut Suspension for the indication of amyotrophic lateral sclerosis.

Radicut Suspension is an oral suspension formulation that contains the same active ingredient as edaravone for intravenous infusion. Formerly, Radicut could only be administered via intravenous infusion in Korea.

Tanabe Pharma Group has developed the oral suspension formulation as a new treatment option for ALS patients to reduce burdens on people living with ALS such as injection pain and outpatient visits. Tanabe Pharma Group is working to provide patients with new drugs that address unmet medical needs, including rare diseases, through our own development and through partnerships with other companies.